Collaboration - August 11, 2017
Lundbeck collaborates on study between genetics and psychiatric disorders
H. Lundbeck joins personal genetics company 23andMe and think tank the Milken Institute in a large new study to increase the understanding of the underlying causes of Major Depressive Disorder (MDD/unipolar depression) and Bipolar Depression. Further, the study will explore how these disorders and brain functions such as attention and decision-making are related to genetics. […]
Clinical Trials - May 10, 2017
Roche’s lung cancer drug receives approval by the Norwegian Medicines Agency
Clinical data from a phase III study of the lung cancer medicine, named Alecensa, also shows significant approved survival for lung cancer patients. The specific form of lung cancer this drugmis approved for, is called anaplastic lymfomkinase (ALK) -positive advanced non-small cell lung cancer (NSCLC). In Norway lung cancer affects about 3 035 people per […]
Drug Development Pharma - April 26, 2017
NeuroVive presents preclinical findings
NeuroVive Pharmaceutical announces positive preclinical results demonstrating anti-fibrotic effects with NV556, the company’s preclinical compound for non-alcoholic steatohepatitis (NASH), in an additional well-validated experimental NASH model. NV556 has previously shown similar anti-fibrotic effects in the experimental STAM™ NASH model. NeuroVive’s scientists present novel data demonstrating anti-fibrotic effects of NV5556 also in the experimental MCD NASH […]
Drug Development Pharma - March 31, 2017
Tagrisso receives US FDA full approval
The US Food and Drug Administration has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. […]
Drug Development Pharma - March 30, 2017
Orphan designation for AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, has announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Developed by MedImmune, inebilizumab is currently in Phase IIb clinical development for NMOSD. “The EMA’s orphan designation for inebilizumab underscores the […]
Collaboration - March 27, 2017
Aprea enters research collaboration
Aprea Therapeutics announces a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246. The goal of the collaboration is to evaluate and characterize preclinical efficacy of APR-246 in combination with multiple other anti-cancer agents and across multiple tumor types. The Principal Investigator of the […]
